Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 14 recruiting now full pipeline

Anemia: full-pipeline trial registry

14 of 74 indexed Anemia trials are currently recruiting.

Corpus placement: #183 of 28,707 conditions by registered trial count.

74 US clinical trials · 14 currently recruiting · #183 of 28,707 conditions by registered trial count

Anemia: 74 US clinical trials tracked, 14 recruiting.

Anemia is the subject of 74 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 26 are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most active sponsor is Akebia Therapeutics, running 5 of these trials.

Enrollment posture brief

Registry condition anemia

OPEN 14 | RECR 19% | LATE 26 | EARLY 25 | RANK #183 | SPON 5

Nearest open-share peer: Colonoscopy (19% recruiting · 21 trials)

Chronic Kidney Diseases62.2%Anatomic Stage II Breast Can54.1%Chronic Myelomonocytic Leuke40.5%Anemia (this)19%HIV Infection12.2%
Open-enrollment share among volume-matched conditions near Anemia

Anemia lists 14 open slots (19% of 74 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Anemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Anemia is recruiting below its size-band peers.

    14 of 74 indexed trials (18.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Anemia trials is spread across many organizations.

    Akebia Therapeutics accounts for 5 of 74 trials (6.8%). 54 distinct sponsors appear on at least one study for this condition label.

  3. Typical Anemia enrolment sits around 161 participants.

    Median target enrolment is 161 among the 73 trials that report a genuine target (sentinel values excluded). 27 of those (37%) plan for fewer than 100 participants.

  4. Anemia research is mostly interventional.

    69 interventional and 5 observational studies make up this index (93.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 16Phase 219Phase 320Phase 46

Open and recent trials

74 total, page 2 of 2

COMPLETED NA 128 participants

Measurement of Total Hemoglobin by Pulse Oximetry in Neonatal Population

Masimo Corporation

NCT03120702

COMPLETED Phase 3 118 participants

Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes

Eastern Cooperative Oncology Group

NCT00003138

COMPLETED Phase 4 110 participants

IV Iron Safety: Evaluation of Iron Species in Healthy Subjects

University of Maryland, Baltimore

NCT02399449

COMPLETED Phase 2 100 participants

Practical Anemia Bundle for SusTained Blood Recovery

Mayo Clinic

NCT05167734

COMPLETED Phase 2 88 participants

Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

Bayer

NCT02064426

COMPLETED NA 80 participants

Umbilical Cord Blood Use For Admission Blood Tests of Very Low Birth Weight Preterm Neonates: A Multi-center Randomized Clinical Trial

Capt Alicia Prescott

NCT02103296

COMPLETED 62 participants

BVA-200 vs BVA-100 Validation Study

Daxor Corporation

NCT06227819

COMPLETED NA 60 participants

Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency

University of Alabama at Birmingham

NCT02888171

COMPLETED Phase 4 59 participants

Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis Patients

Watson Pharmaceuticals

NCT00223964

COMPLETED Phase 2 56 participants

Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)

Mathew S. Maurer

NCT00286182

COMPLETED Phase 2 52 participants

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

Albert Einstein College of Medicine

NCT01772420

COMPLETED 50 participants

Evaluate the Change in Iron, Vitamin D, and C-Reactive Protein Level (CRP) in a 12 to 24 Week Period

Avera McKennan Hospital & University Health Center

NCT01328704

COMPLETED Phase 4 45 participants

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

University of Maryland, Baltimore

NCT00003398

COMPLETED Phase 2 40 participants

Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

Hoffmann-La Roche

NCT03552393

COMPLETED Phase 1 33 participants

A Phase 1 Study of LY2787106 in Cancer and Anemia

Eli Lilly and Company

NCT01340976

COMPLETED NA 32 participants

Placental Transfusion in Term Infants: A Pilot Study

University of Rhode Island

NCT01924572

COMPLETED NA 26 participants

Noninvasive Hemoglobin Repeatability and Reproducibility in a Blood Donation Setting

Masimo Corporation

NCT04490863

COMPLETED Early Phase 1 24 participants

Milking the Umbilical Cord at Term Cesarean Birth

University of Rhode Island

NCT01630993

COMPLETED 12 participants

Effects Of Darbepoetin On Vascular Repair Mechanisms In Kidney Disease The DARBEPC Study

University of Michigan

NCT00396123

COMPLETED Phase 2 11 participants

Iron Sucrose in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients

American Regent

NCT00721188

COMPLETED Phase 2 10 participants

Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Akebia Therapeutics

NCT01235936

COMPLETED Phase 2 8 participants

Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center

NCT02530515

COMPLETED Phase 1 3 participants

BioRBC Survival in Adults With Prior Antibody Response to BioRBCs

John A Widness

NCT02077751

COMPLETED Phase 2

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

Fallon Clinic

NCT00053001

← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 19
Phase 3 20
Phase 4 6

Named interventions

Most-linked intervention names on Anemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
Laboratory Biomarker Analysis Other
4 trials
Darbepoetin alfa Drug
3 trials
epoetin alfa Biological
3 trials
Vadadustat Drug
3 trials
AKB-6548 Drug
2 trials
Venofer Drug
2 trials
Epoetin Alfa Drug
2 trials

US sites by state

Facility locations filed on Anemia trials. A trial with sites in several states counts in each.

California 29 trials
Texas 22 trials
New York 15 trials
Florida 14 trials
Pennsylvania 11 trials
Georgia 11 trials
Missouri 10 trials
Arizona 10 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Anemia page

74 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Anemia condition card totals 74 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.